Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

I.S. Nijhof, R.W.J. Groen, W.A. Noort, B. van Kessel, R. de Jong-Korlaar, J. Bakker, J.J.L. van Bueren, P.W.H.I. Parren, H.M. Lokhorst, N.W.C.J. van de Donk, A.C.M. Martens, T. Mutis

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)2802-2810
JournalClinical Cancer Research
Volume21
Issue number12
DOIs
Publication statusPublished - 2015

Cite this